{"id":"naratriptan-hcl","safety":{"commonSideEffects":[{"rate":null,"effect":"Chest pain or pressure"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Drowsiness"},{"rate":null,"effect":"Paresthesia"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL1200601","moleculeType":"Small molecule","molecularWeight":"371.93"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a triptan, naratriptan is a selective serotonin 5-HT1B/1D receptor agonist that acts on intracranial blood vessels to cause vasoconstriction and reduce the inflammatory cascade associated with migraine. It also inhibits the release of vasoactive neuropeptides from trigeminal nerve terminals, providing dual anti-migraine effects through both vascular and neuronal mechanisms.","oneSentence":"Naratriptan selectively binds to serotonin 5-HT1B/1D receptors on cranial blood vessels and nerve terminals to constrict blood vessels and inhibit neuropeptide release, thereby relieving migraine headaches.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:56:38.767Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute treatment of migraine with or without aura in adults"}]},"trialDetails":[{"nctId":"NCT01161654","phase":"NA","title":"Bioequivalency Study of Naratriptan Hydrochloride 2.5 mg Under Fed Conditions","status":"COMPLETED","sponsor":"Roxane Laboratories","startDate":"2007-08","conditions":"Migraine","enrollment":33},{"nctId":"NCT01161667","phase":"NA","title":"Bioequivalency Study of Naratriptan Hydrochloride 2.5 mg Under Fasted Conditions","status":"COMPLETED","sponsor":"Roxane Laboratories","startDate":"2007-09","conditions":"Migraine","enrollment":35},{"nctId":"NCT01376193","phase":"","title":"Drug Use Investigation for AMERGE (Naratriptan Hydrochloride) Tablet","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-04","conditions":"Migraine Disorders","enrollment":500},{"nctId":"NCT00487578","phase":"PHASE4","title":"Naratriptan for the Treatment of Post Traumatic Headache Associated With Cognitive Dysfunction","status":"TERMINATED","sponsor":"Cady, Roger, M.D.","startDate":"2006-10","conditions":"Post Traumatic Headache","enrollment":12}],"_emaApprovals":[],"_faersSignals":[{"count":8,"reaction":"NAUSEA"},{"count":7,"reaction":"HEADACHE"},{"count":5,"reaction":"CONDITION AGGRAVATED"},{"count":5,"reaction":"DRUG INEFFECTIVE"},{"count":5,"reaction":"MALAISE"},{"count":5,"reaction":"MIGRAINE"},{"count":4,"reaction":"FEELING ABNORMAL"},{"count":4,"reaction":"HOT FLUSH"},{"count":4,"reaction":"HYPERHIDROSIS"},{"count":4,"reaction":"SLEEP APNOEA SYNDROME"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Amerge"],"phase":"marketed","status":"active","brandName":"naratriptan HCl","genericName":"naratriptan HCl","companyName":"Cady, Roger, M.D.","companyId":"cady-roger-m-d","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Naratriptan selectively binds to serotonin 5-HT1B/1D receptors on cranial blood vessels and nerve terminals to constrict blood vessels and inhibit neuropeptide release, thereby relieving migraine headaches. Used for Acute treatment of migraine with or without aura in adults.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}